LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells

Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived growth factor receptor, c-Kit, and Flt-3 signaling, is approved for treatment of advanced hepatocellular carcinoma (HCC). However, the benefit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Int J Med Sci
Main Authors: Ma, Yongfang, Xu, Ruyue, Liu, Xueke, Zhang, Yinci, Song, Li, Cai, Shuyu, Zhou, Shuping, Xie, Yinghai, Li, Amin, Cao, Weiya, Tang, Xiaolong
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2021
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7893555/
https://ncbi.nlm.nih.gov/pubmed/33628103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/ijms.51256
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki